Human histidine-rich glycoprotein was found to interact strongly with heparin both in purified systems and in plasma, resulting in neutralization of the anti-coagulant activity of heparin. In purified systems, histidine-rich glycoprotein and heparin react with apparent 1:1 stoichiometry to form a complex with a dissociation constant of 7 nM. Covalent heparin-antithrombin complex still reacts with histidine-rich glycoprotein to form a complex with a dissociation constant of 29 nM. The interaction between a Mr = 4300-heparin fragment and histidine-rich glycoprotein appeared to be more complex. The mechanism of the interaction between histidine-rich glycoprotein and heparin appeared to be different from that between antithrombin III and heparin, since the former is abolished by EDTA and occurs both with heparin molecules having a high affinity or a low affinity for antithrombin III. In plasma, histidine-rich glycoprotein efficiently counteracts the anticoagulant activity of heparin. Both the thrombin times and the activated factor X inhibition following addition of heparin are markedly prolonged in the absence of histidine-rich glycoprotein and shortened by addition of purified histidine-rich glycoprotein. Low affinity heparin was found to efficiently compete with high affinity heparin for binding to histidine-rich glycoprotein but not to antithrombin III. This results in an increased anticoagulant activity of high affinity heparin in the presence of low affinity heparin. Since the effect of histidine-rich glycoprotein on the anticoagulant properties of heparin is clearly demonstrated in normal plasma, it may be of clinical significance.
No takes yet. Share an insight, caveat, or question.
Lijnen et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: